Nelarabine for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
Young patients with newly diagnosed T-cell acute lymphoblastic leukemia showed favorable outcomes with nelarabine added to a treatment regimen.
Acute Lymphoblastic Leukemia
Genetic Predisposition for Thromboembolism in Adolescent Acute Lymphoblastic Leukemia
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
Development of a Tool to Predict Neurotoxicity Associated With CAR-T Therapy
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
Incorporating Immunotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia
Immunotherapy is changing the treatment paradigm for pediatric patients with relapsed acute lymphoblastic leukemia.
Risk-Stratified Therapy Reduces Late Morbidity, Mortality in Pediatric Acute Lymphoblastic Leukemia
The implementation of risk-stratified therapy appears to have reduced late morbidity and mortality among survivors of pediatric acute lymphoblastic leukemia.
Risk-Adapted Therapy Prevents Fungal Infections in Childhood Leukemia
Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.
Disease-Free Survival Not Improved With Intrathecal Triple Therapy in B-Cell ALL
A study compared the effects of intrathecal triple therapy to intrathecal methotrexate on disease-free survival among patients with B-ALL.
Early-Memory T-Cell Population May Predict CAR-T Efficacy in Several Hematological Malignancies
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
Novel Pediatric Disease Risk Index in Patients With ALL, AML for Allogeneic Hematopoietic Cell Transplantation
Researchers outlined a validated p-DRI for AML and ALL that successfully stratifies children undergoing allogeneic hematopoietic cell transplantation for prognostication.
First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL
A first-in-human, universal CAR-T therapy was tolerable and showed activity against relapsed/refractory T-ALL in a phase 1 study.
-
Loading...
-
Loading...
Next post in Hematologic Cancers
